PAVmed (PAVmed) Interest Expense : $-0.59 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is PAVmed Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. PAVmed's interest expense for the three months ended in Dec. 2023 was $ -0.02 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.59 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. PAVmed's Operating Income for the three months ended in Dec. 2023 was $ -16.38 Mil. PAVmed's Interest Expense for the three months ended in Dec. 2023 was $ -0.02 Mil. PAVmed did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

PAVmed Interest Expense Historical Data

The historical data trend for PAVmed's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PAVmed Interest Expense Chart

PAVmed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.03

-0.05

-1.28

-0.59

PAVmed Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.23	-0.18	-0.23	-0.16	-0.02

PAVmed Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.59 Mil.

PAVmed (NAS:PAVM) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

PAVmed's Interest Expense for the three months ended in Dec. 2023 was $-0.02 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-16.38 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $2.96 Mil.

PAVmed's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

PAVmed did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

PAVmed (PAVmed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PAVmed Inc (NAS:PAVM) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

360 Madison Avenue, 25th Floor, New York, NY, USA, 10017

Website

http://www.pavmed.com

PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard and the Veris Cancer Care Platform.

Executives

Michael J Glennon	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Michael Adam Gordon	officer: General Counsel	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Shaun O'neil	officer: Chief Operating Officer	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
James L Cox	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Debra White	director	C/O PAVMED INC., ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Ronald M Sparks	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Brian J. Deguzman	officer: Chief Medical Officer	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Dennis M Mcgrath	officer: President & CFO	C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Lishan Aklog	director, 10 percent owner, officer: Chairman and CEO	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Joan B Harvey	director	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Timothy E Baxter	director	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Matthew Sirovich	10 percent owner	C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123
Ira Scott Greenspan	director	888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106
David S. Battleman	director	C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
Joshua R Lamstein	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170